News

By: Phil Taylor

BioCryst says oral drug works for HAE attacks

BioCryst Pharma says its oral drug BCX7353 was effective in treating acute hereditary angioedema (HAE) attacks in a midstage trial, setting up a possible registration…


By: Conor Hale

EyeGate’s anti-inflammatory eye drug and electric delivery device fail phase 3 trial

EyeGate Pharmaceuticals’ corticosteroid treatment for noninfectious anterior uveitis—delivered directly into the ocular tissue via the company’s device and a low-level…


By: Conor Hale

Radius Health hires oncology-focused CMO as it moves into breast cancer trials

Endocrine therapy developer Radius Health has brought on Charles Morris to be its new chief medical officer and oversee the company’s expansion into oncology…


By: Conor Hale

Sanofi diabetes VP jumps to NYC metabolic disease startup Applied Therapeutics

Sanofi VP and Senior Medical Officer Riccardo Perfetti, M.D., Ph.D., has made the jump to Applied Therapeutics, a New York-based early-stage biotech focused on…


By: Amirah Al Idrus

CRISPR Therapeutics, Vertex start first company-backed human CRISPR tria

While research groups in China have already started testing CRISPR in humans, CRISPR Therapeutics and Vertex Pharmaceuticals are the first companies to sponsor…